Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck & Co., Inc. : The underlying trend is to the upside

10/14/2020 | 03:46am EST
10/14/2020 | 03:46am EST
long trade
Stop-loss triggered
Entry price : 80.85$ | Target : 86.9$ | Stop-loss : 77.7$ | Potential : 7.48%
Merck & Co., Inc. shares show a positive technical situation which suggests a continuation of the upward dynamic over the medium term.
Investors have an opportunity to buy the stock and target the $ 86.9.
Merck & Co., Inc. : Merck & Co., Inc. : The underlying trend is to the upside
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.

Strengths
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses
  • The company's earnings releases usually do not meet expectations.
  • With an enterprise value anticipated at 4.57 times the sales for the current fiscal year, the company turns out to be overvalued.

© Zonebourse.com 2020

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2020 48 179 M - -
Net income 2020 12 009 M - -
Net Debt 2020 14 601 M - -
P/E ratio 2020 17,3x
Yield 2020 2,98%
Capitalization 206 B 206 B -
EV / Sales 2020 4,59x
EV / Sales 2021 4,23x
Nbr of Employees 71 000
Free-Float 70,7%
Upcoming event on MERCK & CO., INC.
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Average target price 96,33 $
Last Close Price 81,55 $
Spread / Highest target 31,2%
Spread / Average Target 18,1%
Spread / Lowest Target 4,23%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.-10.34%206 324
JOHNSON & JOHNSON1.08%388 168
ROCHE HOLDING AG-4.59%284 650
PFIZER, INC.6.17%219 056
NOVARTIS AG-11.46%205 415
ABBVIE INC.17.51%183 680